타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Leqvio (inclisiran) | Praluent (alirocumab) | Simvastatin |
Overview Company | Amgen | Novartis | Sanofi / Regeneron | Organon and Co |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 (siRNA) | PCSK9 | Lymphoma |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Hyperlipidemia, ASCVD, HeFH | Lymphoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Infrequent dosing (q6 months maintenance) | Flexible q2w dosing; post-ACS outcomes label | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | Injection-site reactions; long-term siRNA durability generally maintained. | resistance to immune checkpoint blockade | — |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | blocks bacterial invasion by targeting key host factors, including collagen I (using FT011), lipid rafts (using simvastatin), integrin β1 (using ATN-161), and FAK signaling |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, PCSK9 protein levels. | LDL-C, ApoB. | biomarkers |
Toxicology Species | Cynomolgus monkey, Hamster | Mouse, Rat | Rat | — |
Toxicology Animal (cat.) | NHP | — | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. | — |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Repatha (evolocumab) | Leqvio (inclisiran) | Praluent (alirocumab) | Simvastatin |
Overview Company | Amgen | Novartis | Sanofi / Regeneron | Organon and Co |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | PCSK9 | PCSK9 (siRNA) | PCSK9 | Lymphoma |
Overview Indication | Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH | Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) | Hyperlipidemia, ASCVD, HeFH | Lymphoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Overview Status | APPROVED | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Watch |
Overview Approval status | FDA approved | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | High LDL-C lowering without statin myalgia; autoinjector pen | Infrequent dosing (q6 months maintenance) | Flexible q2w dosing; post-ACS outcomes label | — |
Positioning Known limitation | Statin non-adherence; rare anti-drug antibodies | Injection-site reactions; long-term siRNA durability generally maintained. | resistance to immune checkpoint blockade | — |
Positioning Development positioning | Add-on to statin ± ezetimibe | — | — | — |
MoA Mechanism | Evolocumab binds PCSK9, preventing PCSK9-mediated LDL receptor degradation on hepatocytes, increasing LDLR recycling and hepatic LDL-C clearance. | Inclisiran is a GalNAc-conjugated siRNA that catalytically degrades PCSK9 mRNA in hepatocytes, reducing PCSK9 protein and increasing LDLR density. | Alirocumab inhibits PCSK9, increasing available LDL receptors and lowering LDL-C similarly to evolocumab. | blocks bacterial invasion by targeting key host factors, including collagen I (using FT011), lipid rafts (using simvastatin), integrin β1 (using ATN-161), and FAK signaling |
MoA Biomarker | LDL-C, ApoB, non-HDL-C; Lp(a) modest reduction. | LDL-C, PCSK9 protein levels. | LDL-C, ApoB. | biomarkers |
Toxicology Species | Cynomolgus monkey, Hamster | Mouse, Rat | Rat | — |
Toxicology Animal (cat.) | NHP | — | — | — |
Toxicology Major finding | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. | — |
Toxicology CRS | N/A | N/A | N/A | — |
Clinical Safety signal | No major organ toxicity; injection-site reactions | Injection-site reactions, arthralgia, urinary tract infection. | Injection-site reactions, flu-like symptoms. | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_1 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | — |
Preclinical Animal (cat.) | Mouse, In vitro | — | — | — |
추천 비교
추천 비교